###begin article-title 0
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
EDN1 Lys198Asn is associated with diabetic retinopathy in type 2 diabetes
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
We tested the hypothesis that genetic variants in vasoactive and angiogenic factors regulating the retina vasculature contribute to the development of diabetic retinopathy (DR).
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 107 111 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 125 128 125 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 169 173 169 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 191 196 191 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ITGA2</italic>
###xml 198 205 198 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BgI II)</italic>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
A case-control study was performed to study the genetic association between DR and polymorphic variants of EDN1 (Lys198Asn), LTA (IVS1-80C>A, IVS1-206G>C, IVS1-252A>G), eNOS (Glu298Asp), and ITGA2 (BgI II) in a Chinese population with type 2 diabetes mellitus. A well defined population with type 2 diabetes, consisting of 127 controls and 216 DR patients, was recruited.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 894 897 894 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 899 903 899 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 908 913 908 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ITGA2</italic>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
###xml 293 301 <span type="species:ncbi:9606">patients</span>
###xml 669 677 <span type="species:ncbi:9606">patients</span>
A higher frequency of the Asn/Asn genotype of EDN1 was found in individuals with at least 10 years of diabetes and no retinopathy (controls) compared with DR patients with any duration of diabetes (DR: 2.3%; control: 11.0%; p=0.0002). The Asn allele was also more frequent in controls than DR patients (DR: 16.4%; control: 29.5%; p=0.007). Multiple logistic regression analysis showed that the Asn/Asn genotype was the factor most significantly associated with reduced risk of DR (odds ratio=0.19; 95% CI: 0.07-0.53; p=0.002) and with late onset of diabetes (Asn/Asn: 59 years; Lys/Lys + Lys/Asn: 53 years; p=0.02). Moreover, the Lys/Lys genotype was more common among patients with nonproliferative (75.7%) than proliferative DR (56.9%; p=0.008). The distributions of Lys198Asn alleles in hypertension did not differ from normotensive subjects. No associations between DR and polymorphisms of LTA, eNOS, or ITGA2 were detected, and there were no detectable gene-gene or gene-environmental interactions among the polymorphisms.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
The Asn/Asn genotype of EDN1 was associated with a reduced risk of DR and with delayed onset of type 2 diabetes.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 331 332 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 567 568 567 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 984 985 984 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
Diabetic retinopathy (DR), a leading cause of blindness worldwide, is a microvascular complication of diabetes characterized by increased vascular permeability and hemostatic abnormalities which can eventually lead to vascular occlusion in spite of antidiabetic treatment and result in retinal nonperfusion and neovascularization [1]. DR is associated with disorders in the nitric oxide (NO) pathway, including impaired NO-mediated vasodilation, increased oxidative and nitrative stress, dysregulation of NO synthase isoforms, and endothelial NO synthase uncoupling [2]. Clinically, DR can be classified into two major categories: early and advanced. Early stage of DR, also called nonproliferative diabetic retinopathy (NPDR), is characterized by edema, leakage of fluid, and limited blood flow into the eye. But NPDR has no abnormal neovascularization. The advanced stage of DR, or proliferative diabetic retinopathy (PDR), involves neovascularization and fibrous tissue formation [3].
###end p 11
###begin p 12
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 284 285 284 285 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
###xml 347 350 347 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR2</italic>
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 528 529 528 529 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
###xml 600 601 600 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 759 763 759 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 781 784 781 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 805 810 805 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ITGA2</italic>
###xml 844 847 844 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACE</italic>
###xml 886 890 886 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 927 932 927 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ICAM</italic>
###xml 936 940 936 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CD45</italic>
###xml 974 981 971 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ADRB3)</italic>
###xml 1001 1005 998 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 1008 1009 1005 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 1010 1011 1007 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 1064 1067 1061 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACE</italic>
###xml 1072 1076 1069 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CD45</italic>
###xml 1607 1608 1604 1605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 478 486 <span type="species:ncbi:9606">patients</span>
Over 30 candidate genes involved in different metabolic mechanisms and functional pathways have been reported to be associated with DR [4,5]. However, only a fraction of them have shown consistent associations with occurrence of DR or its severity in different studies [4,5]. The (CA)n microsatellite marker at the 5'-end of the aldose reductase (AR2) gene is the most frequently reported polymorphism that is associated with DR [4]. Results of our previous study on Chinese DR patients showed that the z-2 allele of the 5'-(CA)n polymorphism was independently associated with DR in type 2 diabetes [6]. Genetic studies have been conducted for vasoactive and angiogenic factors to explore their contributions to DR, such as endothelial nitric oxide synthase (eNOS), lymphotoxin-a (LTA), integrin alpha-2 (ITGA2), angiotensin converting enzyme (ACE), vascular endothelial growth factor (VEGF), intercellular adhesion molecule 1 (ICAM or CD45), beta3-adrenergic receptor gene (ADRB3), and endothelin-1 (EDN1) [4,5]. However, results for some of these genes, such as ACE and CD45, have been inconsistent in various ethnic groups and different study populations. Discrepancies among these studies are likely due to variations in case definition, sample sizes, and medical conditions of control subjects. Some studies selected normal individuals as controls instead of diabetic subjects without DR. Thus, the comparisons were only between normal individuals and diabetic individuals, which may lead to identification of genetic variants associated with vulnerability to diabetes mellitus (DM) rather than to DR [7].
###end p 12
###begin p 13
###xml 496 500 496 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 592 593 592 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 676 680 676 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 685 689 685 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 737 740 737 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 745 751 745 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ITGA2.</italic>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
In this study, we focused on a well-defined population with type 2 diabetes. Only patients without DR but with DM for at least 10 years were selected as controls. We hypothesized that genetic variants in vasoactive and angiogenic factors which regulate the retina vasculature might contribute to the development of retinopathy. We chose polymorphisms previously reported to have positive association with DR, but none have been evaluated in a Chinese DM population. The Lys198Asn polymorphism of EDN1 was also studied because it is associated with hypertension, which is a risk factor of DR [8-11]. We examined six polymorphisms in four genes, including two vasoactive genes, EDN1 and eNOS, and two hemodynamic blood flow related genes, LTA and ITGA2. They have been reported to be associated with vascular diseases in different populations.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Study subjects
###end title 15
###begin p 16
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 1049 1051 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 1180 1181 1178 1179 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1187 1188 1185 1186 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 10 22 <span type="species:ncbi:9606">participants</span>
###xml 343 348 <span type="species:ncbi:9606">human</span>
###xml 496 508 <span type="species:ncbi:9606">participants</span>
###xml 698 706 <span type="species:ncbi:9606">Patients</span>
###xml 779 787 <span type="species:ncbi:9606">Patients</span>
###xml 889 897 <span type="species:ncbi:9606">patients</span>
###xml 1488 1496 <span type="species:ncbi:9606">patients</span>
Unrelated participants with type 2 noninsulin-dependent diabetes mellitus (NIDDM) were recruited from the Eye Clinic of the Prince of Wales Hospital, Hong Kong. Diagnosis of type 2 diabetes was based on WHO criteria [12]. This study was performed in accordance with the ethics standards set by the Declaration of Helsinki. Approval for use of human subjects was obtained from the New Territories East Cluster, Hong Kong, clinical research ethics committee. Informed consent was obtained from the participants after explanation of the nature and possible consequences of the study. DR was diagnosed in a masked manner by independent ophthalmologists by direct ophthalmoscope through dilated pupils. Patients with no signs of DR and with known DM duration <10 years were excluded. Patients without DR but with diabetes duration >/=10 years were designated as control subjects (DM). Diabetic patients with DR were defined as case subjects (DR) either of the NPDR or PDR subtype according to Early Treatment Diabetic Retinopathy Study (ETDRS) criteria [13]. Documented information included age, sex, age at onset of diabetes, duration of diabetes, fast plasma glucose and hemoglobin A1c (HbA1c) level, age at onset of DR, family history, and treatment details. A smoker was defined as someone who smoked at least five cigarettes daily for more than one year. Onset of DR was defined as the first ever documentation of the clinical evidence of DR on the chart. Hyperlipidemia was diagnosed on patients with either elevated total cholesterol (>6.2 mM) or elevated triglycerides (>1.7 mM) requiring either lifestyle modification or pharmacological intervention. Renal failure was defined as persistent and irreversible derangement of the renal function test, typically creatinine >80 muM upon consecutive measurements.
###end p 16
###begin p 17
###xml 651 652 643 644 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 816 823 804 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 26 34 <span type="species:ncbi:9606">patients</span>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 144 152 <span type="species:ncbi:9606">patients</span>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
###xml 536 544 <span type="species:ncbi:9606">patients</span>
###xml 724 732 <span type="species:ncbi:9606">patients</span>
After exclusion of non-DR patients having DM duration of fewer than 10 years, 343 patients were enrolled, consisting of 127 controls and 216 DR patients. Using the allele distributions in non-DR patients, we calculated the statistical power at 80% with a Bonferroni correction significance level of 0.0083, where six comparisons were made, and alpha, before correction was 0.05. Thus the corrected level, alpha / 6 is 0.083 (two-sided) to detect an allele odds ratio of at least 2.2 for eNOS or 1.8 for the other five polymorphisms. DR patients were further divided into NPDR (n=144) and PDR (n=72). DR group showed a significantly higher level of HbA1c (7.35+/-1.36% versus 6.9+/-1.91%, p=0.046) and a higher percentage of patients who underwent insulin treatment (11.5% versus 2.4%, p<0.00001) than control group (Table 1). The PDR group was slightly younger than NPDR and had earlier onset of diabetes. Diabetic macular edema was more common in PDR than in NPDR.
###end p 17
###begin title 18
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Clinical and metabolic characteristics of patients with type 2 diabetes
###end title 18
###begin p 19
###xml 298 306 <span type="species:ncbi:9606">patients</span>
###xml 672 680 <span type="species:ncbi:9606">patients</span>
The table showed the comparisons of the clinical and metabolic characteristics among diabetes mellitus controls (DM) and diabetic retinopathy (DR) and DR subtypes. All p values were computed by chi2 or student t-tests. DR group showed a significantly higher level of HbA1c and higher percentage of patients receiving insulin treatment than controls (1: p=0.046; 2: p<0.00001). By Tukey's test for Post Hoc multiple comparisons (the Bonferroni corrected significance level was 0.025=0.05/2), the significant difference of HbA1c level was only found between nonproliferative diabetic retinopathy (NPDR) and controls (2: p=0.001) and the significant higher percentage of the patients receiving insulin treatment was only due to proliferative diabetic retinopathy (PDR) group (8: p=0.00009). The PDR group was slightly younger than NPDR (4: p=0.001) and controls (5: p=0.00005) and with earlier onset of diabetes than other two groups (6: p=0.0008; 7: p=0.000003). The presence of diabetic macular edema was evident in PDR compared to NPDR (9: p=0.001).
###end p 19
###begin title 20
Genotyping
###end title 20
###begin p 21
###xml 326 330 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 351 354 339 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 568 570 554 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 627 631 612 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 722 725 707 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 860 862 843 845 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2,</sub>
###xml 1078 1082 1047 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 1097 1100 1060 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 1305 1307 1250 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 1451 1452 1396 1397 <strike xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</strike>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
The whole blood specimens (5 ml) from all the patients were collected in EDTA tube and stored at -20 degreesC for fewer than two months' storage. Genomic DNA was extracted from whole blood using the Qiamp kit (Qiagen, Hilden, Germany) and stored at -20 degreesC for fewer than two months before analysis. The polymorphisms of EDN1 (Lys198Asn or ) and LTA (IVS1-80C>A, IVS1-206G>C, and IVS1-252A>G) were detected by polymerase chain reaction (PCR) and direct DNA sequencing. PCR was performed in a final volume of 25 mul containing 2.5 mul of 10X PCR buffer (InvitrogenTM Life Technology, Carlsbad, CA), 0.3 mul of each primer (EDN1: forward 5'- CTT TTG CCA AAG GGT GAT TT-3' and reverse 5'- AGG GTG GAG AGT GCA GAG TC-3'; LTA: forward 5'- TCC TGC CCC ATC TCC TTG G-3' and reverse 5'-AGA GAG AGA GAC AGT GAG CGG G-3'), 0.5 mul of 10 mM dNTP, 1 mul of 50 mM MgCl2, 0.5 U AmpliTaq(R) DNA Polymerase (Applied Biosystems, Foster City, CA), and 10 ng of DNA. After the initial denaturation at 94 degreesC for 3 min, 35 cycles were conducted: 94 degreesC for 30 s, annealing for 30 s (EDN1: 54 degreesC; LTA: 58 degreesC), and 72 degreesC for 30 s. The final extension lasted for 10 min at 72 degreesC. Sequencing was performed using a standard protocol on an automated 3130X DNA sequencer (Applied Biosystems) [14]. Sequence data were analyzed on computer (Chromas ver. 2.13; Technelysium Pty Ltd., Tewantin, QLD, Australia) and compared with published genes sequences from . All rare variants detected were confirmed by bidirectional sequencing.
###end p 21
###begin p 22
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ITGA2</italic>
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
Polymorphisms in eNOS (894G>T) and ITGA2 (IVS8-1059T>C) were analyzed by PCR followed by BanII and BgIII restriction analysis respectively [15,16]. To cross-check the genotyping results, we randomly selected one-fourth of the PCR products for direct sequencing. Complete matching of results was obtained.
###end p 22
###begin title 23
Statistical analysis
###end title 23
###begin p 24
###xml 103 104 101 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 197 198 195 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 238 239 236 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 303 304 299 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Differences in genotype distribution and consistency with Hardy-Weinberg equilibrium were tested by chi2 test. Continuous clinical data (age, age at onset of diabetes, duration of diabetes, and HbA1c) were compared by independent Student t test, and categorical clinical data were compared using the chi2 test or the Fisher's exact test. Tukey's test was used for multiple Post Hoc comparisons, and the Bonferroni method was used for multiple comparison adjustment. To assess the role of gene polymorphisms and search for gene-gene and gene-environmental interactions, we built logistic regression models using various polymorphisms and clinical parameters. Disease status was set as the dependent variable (DR=1; control=0), and gene polymorphisms and environmental factors as independent variables. A stepwise regression approach was used to optimize the analysis. SPSS for Windows, standard version 11.5 (SPSS, Chicago, IL), was used. Statistical significance was defined as p<0.05.
###end p 24
###begin title 25
Results
###end title 25
###begin p 26
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 58 61 58 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 67 72 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ITGA2</italic>
###xml 184 188 184 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 331 338 331 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 548 552 548 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNOS</italic>
###xml 554 560 554 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGTA2,</italic>
###xml 565 568 565 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 660 667 660 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
The distributions of the six polymorphisms of EDN1, eNOS, LTA, and ITGA2 in both case and control groups were under Hardy-Weinberg equilibrium. A significantly higher frequency of the EDN1 Asn/Asn genotype was found in controls than in DR patients (11% versus 2.3%, p=0.0002, Bonferroni corrected significance level 0.0083=0.05/6, Table 2). The Asn allele frequency was also significantly higher in controls than in the DR group (29.5% versus 16.4%, p=0.007, Bonferroni corrected significance level 0.0083). For genotype or allele distributions of eNOS, IGTA2, and LTA polymorphisms, there was no significant difference between DM subjects with or without DR (Table 2).
###end p 26
###begin title 27
Genotype and allele frequencies in groups with and without retinopathy
###end title 27
###begin p 28
###xml 164 183 164 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">endothelin-1 (EDN1)</italic>
###xml 435 439 435 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 289 297 <span type="species:ncbi:9606">patients</span>
The genotype and allele frequency distributions are shown for diabetic retinopathy (DR) and controls (diabetes mellitus without diabetic retinopathy, DM). Only the endothelin-1 (EDN1) Lys198Asn genotype and its allele distributions showed a statistically significant difference between DR patients and controls at the Bonferroni corrected significance level of 0.0083=0.05/6. For comparing DR subtypes and DM distributions of only the EDN1 Lys198Asn polymorphism, the Bonferroni corrected significance level was 0.017=0.05/3.
###end p 28
###begin p 29
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
For the EDN1 polymorphism, we compared DM controls and DR subtypes. NPDR patients had a higher frequency of Lys/Lys than either DM controls or PDR patients (75.7% versus either 56.9% or 52.0% with p=0.0001 and 0.008, respectively, Bonferroni corrected significance level 0.017 = 0.05 / 3), but PDR did not differ from DM controls (p>Bonferroni corrected significance level 0.017). The Asn allele frequency was also significantly higher in controls than in NPDR (29.5% versus 13.5%; p=0.00005, Bonferroni corrected significance level 0.017). However, allele frequencies did not significantly differ among DR subtypes.
###end p 29
###begin p 30
###xml 55 59 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 283 290 283 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 794 801 794 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 910 917 910 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 689 697 <span type="species:ncbi:9606">patients</span>
###xml 755 763 <span type="species:ncbi:9606">patients</span>
Multivariable logistic regression analysis showed that EDN1 Asn/Asn was an independent protective factor for DR after adjustment for age, age at onset of diabetes and insulin therapy. The Odds ratio (OR) was 0.19 with 95% confidence interval (CI) ranging from 0.07 to 0.53 (p=0.002; Table 3). The difference of Lys198Asn genotype distributions between NPDR and PDR was not significant after adjusting for the age at onset of diabetes (p>0.05). But age at onset of diabetes was an independent factor associated with the PDR phenotype (OR=0.94; 95% CI: 0.91-0.97; p=0.00001). We also found no gene-gene or gene-environmental factor interaction in DM samples (p>0.05). The age of DM onset of patients with the Asn/Asn genotype was about six years later than patients with other genotypes (p=0.02; Table 4). Genotype distributions of Lys198Asn were not different between hypertensive and nonhypertensive subjects (Table 4).
###end p 30
###begin title 31
###xml 106 114 <span type="species:ncbi:9606">patients</span>
Odds ratio adjusted by multivariable logistic regression for the association with diabetic retinopathy in patients with type 2 diabetes
###end title 31
###begin p 32
###xml 241 257 241 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1, eNOS, ITGA</italic>
###xml 263 266 263 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 489 493 489 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
The relationship between diabetic retinopathy (DR) and its affected factors were tested by multivariable logistic regression analysis. The presence of DR was regarded as the dependent variable, and independent variables included genotype of EDN1, eNOS, ITGA, and LTA, gender, age, age at onset of diabetes, HbA1c, therapy of insulin, hypertension, and hyperlipidemia. Only items with p values <0.05 were listed. After adjustment for age, age at onset of diabetes and insulin therapy, etc, EDN1 Asn/Asn was the only independent protective factor for DR and younger onset age of diabetes was a significant risk factor for nonproliferative diabetic retinopathy (NPDR) progressing to proliferative diabetic retinopathy (PDR).
###end p 32
###begin title 33
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
Relationship between EDN1genotype, age of diabetes mellitus onset, and hypertension
###end title 33
###begin p 34
###xml 97 101 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 128 136 <span type="species:ncbi:9606">patients</span>
###xml 161 169 <span type="species:ncbi:9606">patients</span>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
The onset age of diabetes mellitus (DM) and hypertension frequency were compared among different EDN1 genotypes in all diabetic patients. The age of DM onset of patients with the Asn/Asn genotype was about six years later than patients with other genotypes (p=0.02) and Lys198Asn genotype distributions were not different between hypertensive and nonhypertensive subjects (p=0.79).
###end p 34
###begin title 35
Discussion
###end title 35
###begin p 36
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 213 216 213 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eNO</italic>
###xml 310 314 310 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 621 626 621 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ITGA2</italic>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 788 791 788 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LTA</italic>
###xml 879 880 879 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 881 883 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
The vasodilator NO and vasoconstrictor endothelin-1 (ET-1) effectively determine the tone of blood vessels [2,17]. Changes in blood flow contribute to early diabetic microangiopathy in DR [18]. Genetic studies on eNOS and risk to DR have shown inconsistent results, and no association between polymorphisms in EDN1 and DR has been identified [19-22]. LTA and ITGA2 are important molecules involved in lymphocyte proliferation and platelet adhesion to subendothelial tissues. They are essential for thrombus formation and contribute to tissue ischemia and activation of neovascularization in DR. The BgIII polymorphism of ITGA2 has been shown to be strongly associated with DR in the Caucasian and Japanese populations [16,23]. There are also ethnic differences in the genetic risk of DR. LTA IVS1-252A>G has been found to be associated with DR in Caucasians but not in Japanese [7,24].
###end p 36
###begin p 37
###xml 42 46 42 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 434 441 434 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
Our study is the first to investigate the EDN1 Lys198Asn polymorphism in a diabetic population. The Asn/Asn frequency was reported to be 6.7% in the Chinese population ( project). We found that the Asn/Asn genotype was higher in DM controls (11.0%) than in DR subjects (2.3%), suggesting a protective role against DR in general. In addition, Asn/Asn was associated with an older age of onset of diabetes, on average a six-year delay (Table 4). Therefore, Asn/Asn might delay DM and protect against progression of DM to NPDR. The Asn/Asn genotype was not associated with hypertension in our DM subjects, indicating that Asn/Asn might not modulate the risk of DR via an effect on hypertension. The frequency of Lys/Lys in PDR (56.9%) was closer to that in DM controls (52.0%; p>0.017) than in NPDR (75.7%; p<0.017). This implies that the pathological mechanisms that lead to NPDR might be different from those in PDR. Lys/Lys might contribute a role in the early breakdown of the blood retinal barrier (as may be the case in NPDR) rather than vascular occlusion and neovascularization (in the case of PDR).
###end p 37
###begin p 38
###xml 651 653 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 654 656 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 1005 1012 1003 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
In this study, we focused on a clinically well defined diabetic population to explore the role of genetic factors in DR progression. Each member of the control group lacked DR but had a >/=10-year history of diabetes. According to the Wisconsin epidemiologic study of diabetic retinopathy (WESDR), the 10-year incidence of DR was almost twice as high as the four year incidence of DR in older onset diabetic subjects (67% versus 34%). In insulin-dependent individuals diagnosed with diabetes before the age of 30 years, the incidence of DR increased from 59% over 4 years to 89% over 10 years, and maintained a similar incidence of 86% over 14 years [25-27]. Thus, a 10-year duration of DM is a reasonable criterion for selecting controls for a DR genetic study. Diabetes duration and glycemic control are major determinants of the development of DR. Our results also showed that subjects who were younger at DM onset had a higher risk of PDR than did subjects with later onset of DM (OR=0.94; p=0.00001; Table 3).
###end p 38
###begin p 39
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 256 260 256 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 573 575 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 1079 1081 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 1126 1130 1126 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 1475 1477 1475 1477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 1652 1654 1652 1654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 1655 1657 1655 1657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 2359 2363 2359 2363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 2466 2468 2466 2468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 134 139 <span type="species:ncbi:9606">human</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
###xml 1426 1431 <span type="species:ncbi:9606">human</span>
ET-1 is implicated in some vascular diseases, including the pathology of DR [28]. EDN1 has also been identified in an early gestation human eye cDNA library and might be important for eye development [29]. The pathogenic significance of the association of EDN1 Lys198Asn with DM and DR remains unknown. Some studies suggested that the Asn allele is associated with increased plasma concentrations of ET-1 [9,10]. However, ET-1 levels in vitreous and aqueous from DR patients were only elevated at the advanced stage of DR (PDR), but decreased in the early stage (NPDR) [17,30]. ET-1 is synthesized from a 212-amino-acid precursor protein (preproET-1) through multiple proteolytic steps. In the first step, preproET-1 is cleaved by signal peptidase, resulting in the formation of proET-1. ProET-1 is then cleaved at the paired dibasic amino acids by a furin-like enzyme to give rise to 38-aminoacid big ET-1 or other intermediates. Big ET-1 is subsequently cleaved at Trp73-Val74 by another endopeptidase, endothelin converting enzyme, resulting in the production of mature ET-1 [31]. A functional in vitro expression study of EDN1 Lys198Asn found that neither ET-1 (bioactive form) nor big ET-1 (intermediate polypeptide) levels in the culture supernatant of the Asn-type transfected cells were significantly changed compared to those of the Lys-type transfected cells in three different cell lines: COS1 cells, 293 cells and human umbilical vein endothelial cells (HUVECs) [32]. Lys198Asn is located near the carboxyl terminal region, which is removed from prepro-ET-1 by the proteolytic action of the furin-like enzyme during the processing of ET-1 [10,33]. This polymorphism may affect the processing of preproET-1 to mature ET-1 rather than modifying the gene expression or the stability of the mRNA. So far there is no data on the functional consequence of the Lys198Asn polymorphism on preproET-1. We hypothesized that the protective effects of 198Asn on diabetes and DR might not exert direct influence on ET-1 production. It could have an impact on the processing of ET-1 or influence linkage disequilibrium with other polymorphisms that affect the production or conformation of the protein. Alterations in ET-1 level or function might affect the response to damage from hyperglycemia and hypoxia in vascular endothelial and other cell types. Another EDN1 polymorphism, a dinucleotide repeat in the 5'-untranslated region, did not have a major impact on DR [19].
###end p 39
###begin p 40
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EDN1</italic>
###xml 138 146 <span type="species:ncbi:9606">patients</span>
In conclusion, we identified the Asn/Asn genotype of EDN1 as a genetic factor for delayed onset of DM and reduced risk of DR in type 2 DM patients. Further studies in other DM types and different ethnic populations should be performed.
###end p 40
###begin title 41
Acknowledgements
###end title 41
###begin p 42
###xml 19 27 <span type="species:ncbi:9606">patients</span>
We are grateful to patients for their participation in this study. This study is supported by a block grant of the Chinese University of Hong Kong and the Li Ka Shing Foundation, Ophthalmology research and training fund.
###end p 42
###begin title 43
References
###end title 43
###begin article-title 44
Important causes of visual impairment in the world today.
###end article-title 44
###begin article-title 45
Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo.
###end article-title 45
###begin article-title 46
Retinal vascular patterns. IV. Diabetic retinopathy.
###end article-title 46
###begin article-title 47
Molecular genetics of microvascular disease in diabetic retinopathy.
###end article-title 47
###begin article-title 48
Genetics of diabetic retinopathy.
###end article-title 48
###begin article-title 49
Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes.
###end article-title 49
###begin article-title 50
Duration of non-Insulin-dependent diabetes mellitus and the TNF-beta NcoI genotype as predictive factors in proliferative diabetic retinopathy.
###end article-title 50
###begin article-title 51
Interactive effects of anger expression and ET-1 Lys198Asn polymorphism on vasoconstriction reactivity to behavioral stress.
###end article-title 51
###begin article-title 52
Association between the endothelin-1 gene Lys198Asn polymorphism blood pressure and plasma endothelin-1 levels in normal and pre-eclamptic pregnancy.
###end article-title 52
###begin article-title 53
###xml 100 106 <span type="species:ncbi:9606">people</span>
The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people.
###end article-title 53
###begin article-title 54
Hypertension and diabetic retinopathy-what's the story?
###end article-title 54
###begin article-title 55
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.
###end article-title 55
###begin article-title 56
Grading diabetic retinopathy from stereoscopic color fundus photographs. An extension of the modified Airlie House classification, ETDRS report number 10.
###end article-title 56
###begin article-title 57
Cost savings using automated DNA sequencing.
###end article-title 57
###begin article-title 58
Association of (-)786T-C mutation of endothelial nitric oxide synthase gene with insulin resistance.
###end article-title 58
###begin article-title 59
Association between diabetic retinopathy and genetic variations in alpha2beta1 integrin, a platelet receptor for collagen.
###end article-title 59
###begin article-title 60
Possible involvement of endothelin-1 and nitric oxide in the pathogenesis of proliferative diabetic retinopathy.
###end article-title 60
###begin article-title 61
Diabetic retinopathy: early functional changes.
###end article-title 61
###begin article-title 62
Dinucleotide repeat polymorphisms in EDN1 and NOS3 are not associated with severe diabetic retinopathy in type 1 or type 2 diabetes.
###end article-title 62
###begin article-title 63
The T-786C and C774T endothelial nitric oxide synthase gene polymorphisms independently affect the onset pattern of severe diabetic retinopathy.
###end article-title 63
###begin article-title 64
Endothelial nitric oxide synthase gene is associated with diabetic macular edema in type 2 diabetes.
###end article-title 64
###begin article-title 65
Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy.
###end article-title 65
###begin article-title 66
BglII gene polymorphism of the alpha2beta1 integrin gene is a risk factor for diabetic retinopathy in Caucasians with type 2 diabetes.
###end article-title 66
###begin article-title 67
###xml 164 172 <span type="species:ncbi:9606">patients</span>
Relationship between polymorphisms 804C/A and 252A/G of lymphotoxin-alpha gene and -308G/A of tumor necrosis factor alpha gene and diabetic retinopathy in Japanese patients with type 2 diabetes mellitus.
###end article-title 67
###begin article-title 68
The Wisconsin epidemiologic study of diabetic retinopathy: an update.
###end article-title 68
###begin article-title 69
The Wisconsin epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy.
###end article-title 69
###begin article-title 70
The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes.
###end article-title 70
###begin article-title 71
A role for endothelin-1 in peripheral vascular disease.
###end article-title 71
###begin article-title 72
###xml 73 78 <span type="species:ncbi:9606">human</span>
Genomic annotation of 15,809 ESTs identified from pooled early gestation human eyes.
###end article-title 72
###begin article-title 73
Concentration of haemodynamic and inflammatory related cytokines in diabetic retinopathy.
###end article-title 73
###begin article-title 74
Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: structure-activity relationships of big endothelin-1.
###end article-title 74
###begin article-title 75
Evaluation of the Lys198Asn and -134delA genetic polymorphisms of the endothelin-1 gene.
###end article-title 75
###begin article-title 76
Endothelin-1 gene variant associates with blood pressure in obese Japanese subjects: the Ohasama Study.
###end article-title 76

